BIO-TECHNE Corp. 10-Q Summary: Fiscal 2026 Q2 (Ended Dec 31, 2025)
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2025 (Fiscal 2026 Q2) and the six months ended December 31, 2025. BIO-TECHNE Corporation develops, manufactures, and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets. The company operates through two reportable segments: Protein Sciences and Diagnostics and Spatial Biology.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Net Sales | $295.9M | $297.0M | $582.4M | $586.5M |
| Gross Margin | $191.3M (64.6%) | $193.9M (65.3%) | $379.4M (65.1%) | $376.9M (64.3%) |
| Operating Income | $54.5M | $47.4M | $102.1M | $87.4M |
| Net Earnings | $38.0M | $34.9M | $76.2M | $68.5M |
| Diluted EPS | $0.24 | $0.22 | $0.49 | $0.42 |
| Cash from Operations (6mo) | $110.0M (vs $148.2M prior year) | |||
| Long-Term Debt | $260.0M (vs $346.0M at June 30, 2025) | |||
| Cash & Equivalents | $172.9M |
Material Changes vs. Prior Period
- Revenue: Consolidated net sales were flat for the quarter (-0.4%) and down 1% for the six-month period. Organic revenue remained flat, with favorable foreign currency impacts (2% for the quarter) offset by the exclusion of revenue from a business held-for-sale (Exosome Diagnostics) in the prior year.
- Profitability: Operating income increased 15% for the quarter and 17% for the six months, driven by cost management initiatives and the divestiture of the Exosome Diagnostics business, which improved the Diagnostics and Spatial Biology segment margin to 10.4% (from 3.9% prior year).
- Debt Reduction: The company repaid $86.0 million of long-term debt during the six-month period, reducing the outstanding balance from $346.0 million to $260.0 million.
- Restructuring: The company recognized a recovery of assets held-for-sale of $6.8 million in the first quarter of fiscal 2026 related to the sale of Exosome Diagnostics. Current quarter restructuring charges were $3.3 million.
Guidance, Outlook, and Risks
- Tax Rate: The effective tax rate for the quarter was 25.2%. Management forecasts the consolidated income tax rate for the remainder of fiscal 2026 to range from 25% to 29% (excluding discrete items).
- Capital Expenditures: Expected capital expenditures for the remainder of fiscal 2026 are approximately $18 million, funded by cash flow and available credit.
- Wilson Wolf Acquisition: The company is obligated to acquire the remaining 80.1% of Wilson Wolf Corporation by December 31, 2027, or earlier if certain revenue/EBITDA milestones are met. The estimated payment is approximately $1 billion plus potential contingent consideration. As of December 31, 2025, the second milestone has not been met.
- Risks: Key risks include integration of acquired businesses, supply chain challenges, foreign currency fluctuations, and the outcome of ongoing legal proceedings (though no material adverse effects are currently expected).
Investor Verification Checklist
- Wilson Wolf Milestones: Verify if Wilson Wolf has met the revenue or EBITDA thresholds that would accelerate the $1 billion acquisition obligation.
- Exosome Diagnostics Divestiture: Confirm the status of the promissory note receivable ($9.0M fair value) and the receipt of MDxHealth stock from the sale.
- Organic Growth Drivers: Analyze the specific product mix shifts in the Protein Sciences segment that led to a 1% organic revenue decline despite favorable currency impacts.
- Debt Covenants: Review the Credit Agreement terms to ensure the reduced debt balance and leverage ratios remain compliant with covenants.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted Net Earnings ($72.1M for Q2) to understand the impact of excluded items like stock-based compensation and amortization.